340 related articles for article (PubMed ID: 14532773)
1. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors.
Zietman AL; Sacco D; Skowronski U; Gomery P; Kaufman DS; Clark JA; Talcott JA; Shipley WU
J Urol; 2003 Nov; 170(5):1772-6. PubMed ID: 14532773
[TBL] [Abstract][Full Text] [Related]
2. Combined modality treatment with selective bladder conservation for invasive bladder cancer: long-term tolerance in the female patient.
Kachnic LA; Shipley WU; Griffin PP; Zietman AL; Kaufman DS; Althausen AF; Heney NM
Cancer J Sci Am; 1996; 2(2):79-84. PubMed ID: 9166504
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
[TBL] [Abstract][Full Text] [Related]
4. Bladder conservation treatment in the elderly population: results and prognostic factors of muscle-invasive bladder cancer.
Tran E; Souhami L; Tanguay S; Rajan R
Am J Clin Oncol; 2009 Aug; 32(4):333-7. PubMed ID: 19381080
[TBL] [Abstract][Full Text] [Related]
5. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
Wo JY; Shipley WU; Dahl DM; Coen JJ; Heney NM; Kaufman DS; Zietman AL
BJU Int; 2009 Jul; 104(2):179-83. PubMed ID: 19154448
[TBL] [Abstract][Full Text] [Related]
6. Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: long term results.
Danesi DT; Arcangeli G; Cruciani E; Altavista P; Mecozzi A; Saracino B; Orefici F
Cancer; 2004 Dec; 101(11):2540-8. PubMed ID: 15481058
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcome of radiation-based conservation therapy for invasive bladder cancer.
Chung PW; Bristow RG; Milosevic MF; Yi QL; Jewett MA; Warde PR; Catton CN; McLean M; Moore M; Tannock IF; Gospodarowicz MK
Urol Oncol; 2007; 25(4):303-9. PubMed ID: 17628296
[TBL] [Abstract][Full Text] [Related]
8. Organ-sparing treatment in muscle-invasive bladder cancer.
Dunst J; Diestelhorst A; Kühn R; Müller AC; Scholz HJ; Fornara P
Strahlenther Onkol; 2005 Oct; 181(10):632-7. PubMed ID: 16220401
[TBL] [Abstract][Full Text] [Related]
9. Editorial: Bladder cancer. How can we make a difference?
Soloway MS
J Urol; 2003 Nov; 170(5):1781-2. PubMed ID: 14532775
[No Abstract] [Full Text] [Related]
10. Complications and long-term results of salvage cystectomy after failed bladder sparing therapy for muscle invasive bladder cancer.
Eswara JR; Efstathiou JA; Heney NM; Paly J; Kaufman DS; McDougal WS; McGovern F; Shipley WU
J Urol; 2012 Feb; 187(2):463-8. PubMed ID: 22177159
[TBL] [Abstract][Full Text] [Related]
11. Lymphovascular invasion of urothelial cancer in matched transurethral bladder tumor resection and radical cystectomy specimens.
Kunju LP; You L; Zhang Y; Daignault S; Montie JE; Lee CT
J Urol; 2008 Nov; 180(5):1928-32; discussion 1932. PubMed ID: 18801529
[TBL] [Abstract][Full Text] [Related]
12. p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach.
Garcia del Muro X; Condom E; Vigués F; Castellsagué X; Figueras A; Muñoz J; Solá J; Soler T; Capellà G; Germà JR
Cancer; 2004 May; 100(9):1859-67. PubMed ID: 15112266
[TBL] [Abstract][Full Text] [Related]
13. Small cell carcinoma of the urinary bladder. The Mayo Clinic experience.
Choong NW; Quevedo JF; Kaur JS
Cancer; 2005 Mar; 103(6):1172-8. PubMed ID: 15700264
[TBL] [Abstract][Full Text] [Related]
14. Association of statin use with improved local control in patients treated with selective bladder preservation for muscle-invasive bladder cancer.
Tsai HK; Katz MS; Coen JJ; Zietman AL; Kaufman DS; Shipley WU
Urology; 2006 Dec; 68(6):1188-92. PubMed ID: 17141846
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcome of high-grade non-muscle-invasive bladder cancer: a long-term single center experience.
Iida S; Kondo T; Kobayashi H; Hashimoto Y; Goya N; Tanabe K
Int J Urol; 2009 Mar; 16(3):287-92. PubMed ID: 19207115
[TBL] [Abstract][Full Text] [Related]
16. Induction cisplatin and fluorouracil-based chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer.
Lin CC; Hsu CH; Cheng JC; Huang CY; Tsai YC; Hsu FM; Huang KH; Cheng AL; Pu YS
Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):442-8. PubMed ID: 19307067
[TBL] [Abstract][Full Text] [Related]
17. Radical hypofractionated accelerated radiotherapy with cytoprotection for invasive bladder cancer.
Koukourakis MI; Tsolos C; Touloupidis S
Urology; 2007 Feb; 69(2):245-50. PubMed ID: 17320657
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
[TBL] [Abstract][Full Text] [Related]
19. Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy?
Weiss C; Wolze C; Engehausen DG; Ott OJ; Krause FS; Schrott KM; Dunst J; Sauer R; Rödel C
J Clin Oncol; 2006 May; 24(15):2318-24. PubMed ID: 16710030
[TBL] [Abstract][Full Text] [Related]
20. Opportunities with combined modality therapy for selective organ preservation in muscle-invasive bladder cancer.
Colvett KT; Althausen AF; Bassil B; Heney NM; McGovern FV; Young HH; Kaufman DS; Zietman AL; Shipley WU
J Surg Oncol; 1996 Nov; 63(3):201-8. PubMed ID: 8944067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
